Vir Biotechnology Names Jason O’Byrne CFO
Vir Biotechnology appoints Jason O’Byrne as CFO, effective October 2, 2024, boosting financial strategy and leadership.
- Latest
- Trending
Vir Biotechnology appoints Jason O’Byrne as CFO, effective October 2, 2024, boosting financial strategy and leadership.
Boehringer Ingelheim acquires Saiba Animal Health, boosting pet R&D with innovative therapeutic vaccines.
Discover why Fortress Biotech's stock is a smart choice for investors seeking both momentum and value in today's market.
Bristol-Myers Squibb-backed Zenas BioPharma files for US IPO as market hopes for rate cuts and reduced volatility rise.
Tecan reports lower H1 2024 sales, revises full-year outlook due to biopharma sector weakness and market challenges in China.
Fortress Biotech reveals Q2 2024 financials with key FDA updates; NDA and BLA filings signal growth in dermatology and oncology.
Legend Biotech reports better-than-expected quarterly earnings, $0.49 EPS above estimates, with significant revenue growth.
Discover Piper Sandler's eight high-quality defensive biotech stocks poised to thrive in volatile markets.
Bruker sees strong growth in Q2 2024, with strategic acquisitions boosting revenues despite challenges in biopharma and Chinese markets.
Personalis sees 35% Q2 revenue growth, lifts full-year outlook to $79-$81M.
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.